$KIDS

Pritzker Jennifer N. sold $943K of KIDS (indirect holdings)

Pritzker Jennifer N. sold 38,300 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $24.63 ($24.28–$25.75, $0.94M total) across 3 trades over 2026-08-24 to 2026-08-26.

Original reporting
SEC EDGAR · Pritzker Jennifer N.
Published Aug 26, 2026, 10:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KIDS
Bearish
medium confidence
Mentioned
$KIDS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSBearishLow
01

Why it matters

The sale reduces insider ownership and may affect investor perception.

02

Market read

Insider sale of sub‑$1M size, modest relevance for traders.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-26

Background

Form 4 filing reports insider transactions for public companies.

Company-level read

Ticker impact

$KIDSBearishMedium confidence
Context

Jennifer N. Pritzker sold 38,300 shares for $943k, reducing her stake in Orthopedics Corp.

Expected impact

Possible modest decline or increased volatility.

Evidence & confidence

10% owner selling nearly $1M of stock; market may interpret as negative signal.

Market effects

Minimal impact on orthopedics sector.

None.

Low.

Counterpoint

Sale could be routine liquidity need, not a bearish signal.

Key entities

  • Jennifer N. Pritzker

    10% owner of Orthopedics Corp.

  • Orthopedics Corp.

    Issuer of ticker KIDS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KIDSMed

OrthoPediatrics Corp. Q2 2026 Earnings Call Summary

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.